RecruitingRelapsed CancerRefractory Multiple MyelomaMultiple Myeloma
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.
Sponsor: Massachusetts General Hospital
You may qualify if…
- ✓ Participant has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to their future medical care.
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (see Appendix A).
- ✓ Age ≥ 18 years
- ✓ Measurable disease of multiple myeloma as defined by at least one of the following:
- ✓ Serum monoclonal protein ≥ 0.5 g/dL. Patients with IgD disease and lower amounts of monoclonal protein may be permitted to enroll with PI approval
- ✓ ≥ 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
- ✓ Involved serum free light chain ≥ 100 mg/L (10 mg/dL) and abnormal serum free light chain ratio
- ✓ Previously treated relapsed and refractory multiple myeloma:
You may not qualify if…
- ✕ Participant must not have had current corneal epithelial disease except mild changes in corneal epithelium.
- ✕ Participant must not use contact lenses while participating in this study.
- ✕ Participants who have had myeloma therapy or investigational drug within 2 weeks prior to start of treatment or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
- ✕ Participants who are receiving any investigational agents.
- ✕ Prior therapy with anti-CD38 monoclonal antibody within six months. No other multiple myeloma monoclonal antibody therapy within 30 days of start of study treatment.
- ✕ Prior therapy with anti-BCMA therapy.
- ✕ Plasmapheresis within seven days prior to start of study treatment.
- ✕ Primary refractory disease.
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT05922501 · last updated 2026-01-14